Author

D. Decaudin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:cancer & tumor microenvironment· 1 Organism:mouse· 1

Frequent Co-Authors

F. Nemati· 4 shared S. Roman-Roman· 2 shared A. Bellini· 1 shared A. Brisson· 1 shared A. Carcaboso· 1 shared A. G. Jochemsen· 1 shared A. Goodman· 1 shared A. Groenewoud· 1 shared

Activity by Year

2021-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

F. Nemati

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

COMBINATION THERAPIES TARGETING ALK-ABERRANT NEUROBLASTOMA IN PRECLINICAL MODELS.

E. Tucker, I. Jimenez, L. Chen, A. Bellini, C. Gorrini, E. Calton, Q. Gao, H. Che, E. Poon, Y. Jamin, B. Martins da Costa, K. Barker, S. Shrestha, C. Hutchinson, S. Dhariwal, , G. Schleiermacher

This study evaluates lorlatinib, an ALK inhibitor, in combination with chemotherapy or idasanutlin in preclinical neuroblastoma models, finding synergy in models with high ALK expression.

Clinical Cancer Research · Apr 3, 2023Peer-reviewedCancer Biology

Uveal Melanoma: a miR-16 disease?

A. M. Quemener, L. Bachelot, M. Aubry, S. Avner, D. Leclerc, G. Salbert, F. Cabillic, D. Decaudin, B. Mari, F. Mouriaux, M.-D. Galibert, D. Gilot

This study identifies miR-16's non-canonical role in uveal melanoma by sequestering sponge RNAs, leading to oncogene derepression and poor survival, with a sponge-signature outperforming current methods.

bioRxiv · Nov 30, 2021Cancer Biology

Patient-derived zebrafish xenograft models reveal ferroptosis as a fatal and druggable weakness in metastatic uveal melanoma

A. Groenewoud, J. Yin, M. C. Gelmi, S. Alsafadi, F. Nemati, D. Decaudin, S. Roman-Roman, H. Kalirai, S. E. Coupland, A. G. Jochemsen, M. J. Jager, E. Snaar-Jagalska

The paper develops a zebrafish xenograft model of metastatic uveal melanoma and identifies ferroptosis as a druggable vulnerability in tumors with BAP1 loss.

bioRxiv · Oct 26, 2021 · PreprintCancer Biology

PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancer

S. Suresh, S. Huard, A. Brisson, F. Nemati, C. Poulard, M. Ye, E. Martel, C. Reyes, D. C. Silvestre, D. Meseure, A. Nicolas, D. Gentien, M. Le Romancer, D. Decaudin, S. Roman-Roman, T. Dubois

This study identifies PRMT1 as a key regulator of EGFR and Wnt signaling in breast cancer and shows that targeting it with inhibitors can enhance chemotherapy and EGFR inhibitor efficacy in TNBC.

bioRxiv · Oct 22, 2021Cancer Biology

The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival

S. Dewaele, L. Delhaye, B. De Paepe, E. De Bony, J. De Wilde, K. Vanderheyden, J. Anckaert, N. Yigit, E. VandenEynde, F. Nemati, D. Decaudin, A. Jochemsen, E. Leucci, J. Vandesompele, J. Van Dorpe, , P. Mestdagh

This study shows that inhibiting the lncRNA SAMMSON reduces uveal melanoma cell growth and viability by impairing mitochondrial function and protein translation.

bioRxiv · Jan 18, 2021Cancer Biology